It is worth considering that
it is not just these naval personnel who are at risk from lead
toxicity. The degree of general human body contamination with
lead is now at five hundred times the level of people living
just two hundred years ago. Lead has many toxic effects on the
body, one of the more serious being its ability to prevent the
body's natural control of free radical activity which itself
can result in circulatory incompetence as well as many other
problems.
Research studies by doctors
such as Belknap, Butler, Spencer, Foreman, Clarke, Dudley, Bechtel,
Jick, Surawicz, Boyle, Perry, Kitchell and many more (see References),
published in the early and middle 1950s, all relate to aspects of the treatment of arterial disease using EDTA.
Since those pioneering days,
techniques have evolved and have been improved for the successful
application of EDTA chelation treatment of the disastrous effects
not only of atherosclerosis, but also of circulatory obstructions
to the brain in people with some forms of senility. Similar benefits
have often been observed amongst those who have experienced cerebral
accidents (stroke) or who are suffering from early gangrenous
conditions. (The way in which EDTA is thought to work is discussed
in chapter 5.) Relief and marked symptomatic improvement has
been gained in countless instances of high blood pressure (essential
hypertension) and problems involving peripheral circulation (Reynaud's
disease) as well as occlusion of blood flow to the extremities
(intermittent claudication).
A description of one of the
earliest uses of EDTA in treating chronic cardiovascular disease
was given in 1976 by Dr. Norman Clarke, Sr., to the California
Medical Association, in testimony before its Advisory Panel on
Internal Medicine. He described his introduction to the process
by research doctors (Drs. Albert Boyle and Gordon Myers) at Wayne University, Detroit in 1953.
They had had preliminary experience
in treating two patients at University Hospital, Detroit, who
had calcified mitral valves. The patients were almost completely
incapacitated . . . the doctors were very pleased with the results
[of chelation treatment] because they obtained very satisfactory
return of cardiac function.
Dr Clarke spent many years
investigating EDTA's usefulness in treating cardiovascular disease,
and in his evidence stated: 'In the last 28 years of my experience
with EDTA chelation I have given at least 100,000 to 120,000
infusions of EDTA and seen nobody harmed'.
He dramatically described
the successful treatment of gangrene using EDTA, perfused directly
into the site via a drip into the femoral artery, as well as
this method's usefulness in cerebrovascular senility: 'After
all these years, and with all that experience, I am just as certain
as can be that EDTA chelation therapy is the best treatment that
has ever been brought out for occlusive vascular disease'
Other benefits
from EDTA infusion
Just as the use of EDTA in
treating lead poisoning revealed its ability to remove unwanted
calcium, so additional benefits were discovered when circulatory
conditions were being treated. Many patients with osteoarthritic
and similar problems reported relief of symptoms and an improved
range of movement in previously restricted joints. It seems that
obstructive calcium deposits in these areas were also being removed
during chelation treatment.